Photodynamic inactivation of multi-resistant bacteria (PIB) - A new approach to treat superficial infections in the 21st century;Photodynamische inaktivierung von multiresistenten bakterien (PIB) - Ein neuer ansatz zur behandlung oberflächlicher infektionen im 21. jahrhundert

JDDG - Journal of the German Society of Dermatology

Volumn 9, Issue 5, 2011, Pages 360-366

  Maisch, Tim ^a   Hackbarth, Steffen ^b   Regensburger, Johannes ^a   Felgenträger, Ariane ^a   Bäumler, Wolfgang ^a   Landthaler, Michael ^a   Röder, Beate ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

colonization; light; MRSA; photodynamic; singlet oxygen

Indexed keywords

CEFDITOREN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; FULLERENE DERIVATIVE; GATIFLOXACIN; GEMIFLOXACIN; LINEZOLID; MOXIFLOXACIN; NATURAL PRODUCT; PHENOTHIAZINE; PSEUDOMONIC ACID; RETAPAMULIN; RIFAPENTINE; TETRAPYRROLE DERIVATIVE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACNE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG APPROVAL; DRUG MECHANISM; ENTEROBACTER; ENTEROCOCCUS FAECIUM; HUMAN; IMPETIGO; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHOTOCHEMISTRY; PHOTODYNAMIC INACTIVATION OF MULTI RESISTANT BACTERIUM; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHYSICAL CHEMISTRY; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 79955057574     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07577.x     Document Type: Review

References (50)

1. Arias CA, Murray BE,. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009; 360: 439-43.
2. Rice LB,. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81. (Pubitemid 351590040)
3. Appelbaum PC,. MRSA-the tip of the iceberg. Clin Microbiol Infect 2006; 12 (Suppl 2): 3-10. (Pubitemid 43355765)
4. EARSS MT. EARSS Annual Report 2007. http://wwwrivmnl/en/. 2008: www.rivm.nl/earss
5. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R,. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42: 389-91. (Pubitemid 43122317)
6. Fridkin SK,. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108-15. (Pubitemid 32150955)
7. Patel JB, Gorwitz RJ, Jernigan JA,. Mupirocin resistance. Clin Infect Dis 2009; 49: 935-41.
8. Rietschel RL,. Dermatologic manifestations of antimicrobial adverse reactions with special emphasis on topical exposure. Infect Dis Clin North Am 1994; 8: 607-15. (Pubitemid 24315340)
9. Harkaway KS, McGinley KJ, Foglia AN, Lee WL, Fried F, Shalita AR, Leyden JJ,. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992; 126: 586-90.
10. Cerveny KE, DePaola A, Duckworth DH, Gulig PA,. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 2002; 70: 6251-62. (Pubitemid 35192717)
11. Sajjan US, Tran LT, Sole N, Rovaldi C, Akiyama A, Friden PM, Forstner JF, Rothstein DM,. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 2001; 45: 3437-44. (Pubitemid 33107859)
12. Mettler E,. Experimentelles über die bakterizide Wirkung des Lichtes auf Eosin, Erythrosin und Fluoreszein gefärbte Nährböden. Arch Hyg 1905; 53: 79-127.
13. Röder B,. Photodynamic Therapy. John Wiley & Sons Ltd, Chichester, 2000.
14. Nikaido H, Vaara M,. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985; 49: 1-32. (Pubitemid 15134118)
15. Maisch T, Wagner J, Papastamou V, Nerl HJ, Hiller KA, Szeimies RM, Schmalz G,. Combination of 10 % EDTA, Photosan, and a blue light hand-held photopolymerizer to inactivate leading oral bacteria in dentistry in vitro. J Appl Microbiol 2009; 107: 1569-78.
16. Vaara M, Vaara T,. Polycations as outer membrane-disorganizing agents. Antimicrob Agents Chemother 1983; 24: 114-22. (Pubitemid 13076188)
17. Maisch T, Bosl C, Szeimies RM, Lehn N, Abels C,. Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells. Antimicrob Agents Chemother 2005; 49: 1542-52. (Pubitemid 40463386)
18. Minnock A, Vernon DI, Schofield J, Griffiths J, Parish JH, Brown ST,. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both gram-negative and gram-positive bacteria. J Photochem Photobiol B 1996; 32: 159-64. (Pubitemid 26127372)
19. Wainwright M, Phoenix DA, Marland J, Wareing DR, Bolton FJ,. A study of photobactericidal activity in the pheno-thiazinium series. FEMS Immunol Med Microbiol 1997; 19: 75-80. (Pubitemid 27402033)
20. Demidova TN, Hamblin MR,. Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother 2005; 49: 2329-35. (Pubitemid 40734462)
21. Moan J, Berg K,. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53: 549-53.
22. Schafer M, Schmitz C, Horneck G,. High sensitivity of Deinococcus radiodurans to photodynamically-produced singlet oxygen. Int J Radiat Biol 1998; 74: 249-53. (Pubitemid 28372552)
23. Chapple RM, Inglis B, Stewart PR,. Lethal and mutational effects of solar and UV radiation on Staphylococcus aureus. Arch Microbiol 1992; 157: 242-8.
24. Musher DM, Lamm N, Darouiche RO, Young EJ, Hamill RJ, Landon GC,. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine (Baltimore) 1994; 73: 186-208. (Pubitemid 24245108)
25. Hamblin MR, O'Donnell DA, Murthy N, Contag CH, Hasan T,. Rapid control of wound infections by targeted photodynamic therapy monitored by in vivo bioluminescence imaging. Photochem Photobiol 2002; 75: 51-7.
26. Berthiaume F, Reiken SR, Toner M, Tompkins RG, Yarmush ML,. Antibody-targeted photolysis of bacteria in vivo. Biotechnology (NY) 1994; 12: 703-6.
27. Zolfaghari PS, Packer S, Singer M, Nair SP, Bennett J, Street C, Wilson M,. In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent. BMC Microbiol 2009; 9: 27.
28. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A,. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001; 144: 575-9. (Pubitemid 32232014)
29. Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR,. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000; 115: 183-92. (Pubitemid 30637186)
30. Pollock B, Turner D, Stringer MR, Bojar RA, Goulden V, Stables GI, Cunliffe WJ,. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004; 151: 616-22. (Pubitemid 39330886)
31. Fabbrocini G, Cacciapuoti S, De Vita V, Fardella N, Pastore F, Monfrecola G,. The effect of aminolevulinic acid photodynamic therapy on microcomedones and macrocomedones. Dermatology 2009; 219: 322-8.
32. Kim BJ, Lee HG, Woo SM, Youn JI, Suh DH,. Pilot study on photodynamic therapy for acne using indocyanine green and diode laser. J Dermatol 2009; 36: 17-21.
33. Jekler J,. Phototherapy of atopic dermatitis with ultraviolet radiation. Acta Derm Venereol Suppl (Stockh) 1992; 171: 1-37.
34. Schempp CM, Effinger T, Czech W, Krutmann J, Simon JC, Schopf E,. [Characterization of nonresponders in high dosage UVA1 therapy of acute exacerbated atopic dermatitis]. Hautarzt 1997; 48: 94-9. (Pubitemid 27138074)
35. McLinn S,. A bacteriologically controlled, randomized study comparing the efficacy of 2 % mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol 1990; 22: 883-5. (Pubitemid 20154109)
36. Gisby J, Bryant J,. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 2000; 44: 255-60. (Pubitemid 30060715)
37. Rossney AS, Keane CT,. Strain variation in the MRSA population over a 10-year period in one Dublin hospital. Eur J Clin Microbiol Infect Dis 2002; 21: 123-6.
38. Kedzierska A, Kapinska-Mrowiecka M, Czubak-Macugowska M, Wojcik K, Kedzierska J,. Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization. Br J Dermatol 2008; 159: 1290-9.
39. Shittu AO, Lin J,. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa. BMC Infect Dis 2006; 6: 125.
40. Hoiby N, Jarlov JO, Kemp M, Tvede M, Bangsborg JM, Kjerulf A, Pers C, Hansen H,. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349: 167-9. (Pubitemid 27039196)
41. Vaara M, Vaara T, Jensen M, Helander I, Nurminen M, Rietschel ET, Makela PH,. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett 1981; 129: 145-9. (Pubitemid 11037531)
42. Harder KJ, Nikaido H, Matsuhashi M,. Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin. Antimicrob Agents Chemother 1981; 20: 549-52. (Pubitemid 12239275)
43. Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS,. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 2001; 45: 280-7. (Pubitemid 32039127)
44. Grinholc M, Szramka B, Kurlenda J, Graczyk A, Bielawski KP,. Bactericidal effect of photodynamic inactivation against methicillin-resistant and methicillin-susceptible Staphylococcus aureus is strain-dependent. J Photochem Photobiol B 2008; 90: 57-63.
45. Bronshtein I, Afri M, Weitman H, Frimer AA, Smith KM, Ehrenberg B,. Porphyrin depth in lipid bilayers as determined by iodide and parallax fluorescence quenching methods and its effect on photosensitizing efficiency. Biophys J 2004; 87: 1155-64. (Pubitemid 39095092)
46. Maisch T, Worlicek C, Babilas P, Landthaler M, Szeimies RM,. A HCl/alcohol formulation increased 5-aminolevulinic acid skin distribution using an ex vivo full thickness porcine skin model. Exp Dermatol 2008; 17: 813-20.
47. Spellberg B,. Antibiotic resistance and antibiotic development. Lancet Infect Dis 2008; 8: 211-2; author reply 12-4. (Pubitemid 351382021)
48. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE, Jr,. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279-86. (Pubitemid 38608571)
49. Maisch T, Szeimies RM, Lehn N, Abels C,. [Antibacterial photodynamic therapy. A new treatment for bacterial skin diseases?]. Hautarzt 2005; 56: 1048-55. (Pubitemid 41586700)
50. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA,. für die Studiengruppe Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlich-keitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2007. Antiinfectives Intelligence, Rheinbach, 2009.